Form 4: Raphael Pharmaceuticals Director Yehuda Eliya Reports Changes in Beneficial Ownership

Director Yehuda Eliya reports the expiration of 202,000 warrants and receipt of 200,000 new warrants in Raphael Pharmaceuticals.

Summary

• Yehuda Eliya, a director of Raphael Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On May 12, 2024, 202,000 warrants to purchase common stock expired.
• On March 10, 2025, Eliya received 200,000 warrants as compensation for serving as a director.
• These new warrants are exercisable immediately and expire on March 10, 2026.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without indicating positive or negative performance.

Positives

• The receipt of 200,000 warrants by a director could be seen as an incentive aligning their interests with shareholders.

Negatives

• The expiration of 202,000 warrants represents a decrease in potential ownership for the director.

Risks

• The value of the warrants is dependent on the future performance of Raphael Pharmaceuticals' stock.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Related Party Transactions

• The receipt of warrants by Yehuda Eliya is a related party transaction as he is a director of Raphael Pharmaceuticals.

Stakeholder Impact

• The changes in beneficial ownership may have a minor impact on shareholders, depending on the perceived value of the warrants and the director's alignment with shareholder interests.

Key Dates